Gitnux/Report 2026

Contract Research Organization Industry Statistics

The global CRO services market is projected at $99.87 billion in 2026, explore the latest growth, company data, and operational trends.
304Statistics
60Sources
12Sections
1Visuals
49mRead
November 11, 2026Updated
Contract Research Organization Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The contract research organization industry at a glance

The global contract research organization services market was valued at $92.27 billion in 2025 and is expanding as pharmaceutical and biotechnology companies outsource increasingly complex development work.

$92.27B[53]
Global market size, 2025
9.0%[53]
Forecast CAGR, 2026–2034
470,000+[1]
CRO employees, 2025
50.08%[53]
North America share, 2025
Market size
The global CRO services market was valued at $92.27 billion in 2025 and is projected to reach $99.87 billion in 2026. North America accounted for $46.21 billion in 2025.[53]
Forecast & CAGR
The market is forecast to reach $199.28 billion by 2034, representing a 9.0% CAGR from 2026 to 2034. A separate 2026 estimate places the market at $93.02 billion and projects $140.32 billion by 2031, equivalent to an 8.6% CAGR, reflecting differences in market scope and methodology.[53][54]
Market share & regions
North America led the market with a 50.08% share in 2025. Asia Pacific is projected to reach $19.45 billion in 2026 and is expected to record the fastest growth, while Europe is projected to reach $25.77 billion in 2026 and grow at a 7.9% CAGR through 2034.[53]
Segmentation
Early-phase development services represented the largest service segment, with a 40.74% share in 2025. The market is also segmented by clinical research services, laboratory services, therapeutic area, outsourcing model, and end user; oncology is projected to hold a 29.7% share in 2026.[53]
Key players & concentration
Major providers include IQVIA, ICON, Syneos Health, Charles River Laboratories, and Medpace. IQVIA reported $16.31 billion in total revenue in 2025, including $8.896 billion from Research & Development Solutions, while ICON reported $8.251 billion in 2025 revenue; these figures are company revenues and are not directly comparable with the narrower CRO-services market total.[18][43]
Trends, drivers & challenges
Demand is being supported by more complex clinical programs, increased biotechnology activity, patient-centric and decentralized trials, and the use of AI in clinical-trial workflows. Operational and compliance risks remain material: the FDA said in 2025 that certain studies conducted by Raptim Research, an Indian CRO, were unacceptable because of data-integrity and study-conduct concerns.[54][46]
Consumer behavior & competition
CRO demand is primarily driven by pharmaceutical, biotechnology, medical-device, and academic sponsors rather than household consumers. ACRO member companies reported working with an estimated 592 sponsor companies in 2025, conducting or participating in 7,634 studies involving 1.4 million patients and volunteers; competition centers on global delivery, therapeutic expertise, data capabilities, and integrated services.[1]
Regulation
CROs perform sponsor-delegated trial functions and remain subject to regulatory expectations for data integrity, study conduct, and clinical or bioanalytical documentation. In March 2025, the FDA notified pharmaceutical companies that certain studies conducted by Raptim Research were unacceptable after identifying data-integrity and study-conduct concerns.[46]
Latest news
The Association of Clinical Research Organizations published its 2025 State of the Industry Report in March 2026. Its 15 member companies reported more than 470,000 employees worldwide, $89.4 billion in 2025 revenue, 7,634 studies, and 1.4 million patients and volunteers managed or supported.[1]

02 Ranking

Top 10 Companies in the Contract Research Organization Industry

The leading companies in the contract research organization industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

IQVIA stands out for Research & Development Solutions delivery because it reported $8.896 billion in 2025 revenue, while Labcorp is the pick for drug development laboratory work since it provides capabilities serving clients in about 100 countries.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in clinical research services

    IQVIA

    US

    Ranked #1 · 9.1 · Clinical research services

    Why we picked it: Its Research & Development Solutions channel ties to a $8.896 billion 2025 revenue level, alongside data and analytics activity.

    See in ranking ↓Visit iqvia.com ↗

  2. Leader in drug development laboratories

    Labcorp

    US

    Ranked #2 · 9.1 · Drug development laboratories

    Why we picked it: Its scale across roughly 100 countries pairs with drug development laboratory capabilities for sponsor-delegated work.

    See in ranking ↓Visit labcorp.com ↗

  3. Leader in integrated discovery to clinical

    WuXi AppTec

    CN

    Ranked #4 · 8.9 · Integrated discovery to clinical

    Why we picked it: Integrated discovery through clinical research services support outward delivery of complex development work.

    See in ranking ↓Visit wuxiapptec.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the contract research organization industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

IQVIA

Clinical research services · US

9.1
2

Labcorp

Drug development laboratories · US

9.1
3

Thermo Fisher Scientific

Clinical research services · US

8.9
4

WuXi AppTec

Integrated discovery to clinical · CN

8.9
5

Medpace

Clinical research services · US

8.9
6

Parexel

Global clinical development and regulatory services · US

8.4
7

Charles River Laboratories

Preclinical discovery, safety assessment and research services · US

8.2
8

Syneos Health

Integrated clinical development and biopharma services · US

8.1
9

Altasciences

Integrated preclinical and early clinical development · CA

7.9
10

Worldwide Clinical Trials

Global clinical trials and therapeutic development · US

7.8

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the contract research organization industry. In Contract Research Organization Industry Statistics. Gitnux. https://gitnux.org/contract-research-organization-industry-statistics/#top-companies

report visual · Comparison

Revenue of the largest contract research organization companies

Thermo Fisher Scientific leads with $44.6B in annual revenue (group level, converted to USD).

Thermo Fisher Scientific$44.6B
IQVIA$16.3B
Labcorp$14.0B
WuXi AppTec$6.4B
Charles River Laboratories$4.0B
Medpace$2.5B
source-verifiedcorporate.thermofisher.com · ir.iqvia.com · labcorp.com · wuxiapptec.cn · ir.criver.com · investor.medpace.com2025

04 Statistics

Technology & Innovation

Technology adoption shows up in scale and throughput: ACRO members supported 1.4 million patients and volunteers in 2025, with 7,634 studies conducted or supported.

AI in the contract research organization industry

  • 48,794 ACRO member employees were located in India in 2025.[1]
  • 125,498 ACRO member employees were located in the United States in 2025.[1]
  • 175 million patient encounters per year were reported by Labcorp in its 2025 proxy statement while describing AI and machine-learning use in clinical development services.[2]
  • $89.4 billion in revenue was generated by ACRO member companies in 2025.[1]
  • 15 ACRO member companies participated in the organization’s 2025 survey on CRO industry activities and AI adoption.[1]
  • 15,061 ACRO member employees were located in the United Kingdom in 2025.[1]

Automation in the contract research organization industry

  • 7,634 studies were conducted or supported by ACRO members in 2025 across clinical research operations that can use automated workflows.[1]
  • 1.4 million patients and volunteers were managed by ACRO member companies in 2025 through CRO study operations.[1]
  • 33% of clinical research professionals surveyed in 2025 believed clinical-trial operations were efficient, indicating substantial room for CRO automation.[3]
  • More than 470,000 employees worked for ACRO member companies worldwide in 2025, supporting the sector’s technology-enabled delivery model.[1]
  • $89.4 billion in revenue was generated by ACRO member companies in 2025 while they expanded risk-based and technology-enabled operations.[1]
  • 4,296 outsourced studies were covered by ACRO’s 2025 risk-based quality-management technology survey.[1]

Digital Transformation in the healthcare services sector (sector benchmark)

  • About 90% of surveyed global healthcare C-suite executives expected digital technology use to accelerate in 2025, including 50% anticipating a significant impact.[4]
  • Across U.S. non-federal acute care hospitals, 71% used predictive AI integrated into electronic health records in 2024.[5]
  • About 70% of surveyed healthcare executives said investing in technology platforms for digital tools and services would be important or very important in 2025.[4]
  • Across surveyed healthcare practitioners, 60% believed their organizations’ digital experiences met or exceeded customer needs in 2025.[6]
  • Among healthcare respondents to KPMG’s global technology survey, 49% were adopting DevSecOps approaches to adapt digital-transformation strategies.[7]

Technology Adoption in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 99% enabled patients to view health information electronically in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 81% enabled patient access through applications using application-programming-interface specifications in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 96% enabled patients to download health information electronically in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 70% enabled patient access through applications using HL7 FHIR specifications in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 92% enabled patients to securely message providers in 2024.[5]
  • Across U.S. non-federal acute care hospitals, 84% enabled patients to transmit health information to a third party electronically in 2024.[5]

Cloud Computing in the healthcare services sector (sector benchmark)

  • Across surveyed healthcare organizations globally, 31% had a formal cloud strategy and governance framework that was not yet integrated into IT strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 27% reported that cloud operations were well managed and integrated into overall IT strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 18% had started adopting cloud services but lacked a comprehensive cloud strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 15% reported that cloud adoption was fully integrated into business strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 8% reported minimal cloud adoption without formal strategy or governance at the end of 2025.[8]

Big Data in the healthcare services sector (sector benchmark)

  • Across Brazilian healthcare facilities conducting Big Data analytics, 65% used patient demographics, forms, or medical-record data in 2024.[9]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 48% used social-media data in 2024.[9]

05 Statistics

Data & Analytics

Data readiness and governance remain differentiators, with 82% of CRO survey respondents creating specifications for analysis-ready datasets in 2025 and IQVIA holding 68 petabytes of unique data in 2025.

Business intelligence in the contract research organization industry

  • 74% of surveyed CROs cited better visibility and oversight as a main driver for unifying clinical applications in 2019.[3]
  • 58% of surveyed CROs used electronic trial master file systems to increase visibility into trial-master-file status in 2019.[3]
  • 68% of surveyed CROs cited faster trials as a main driver for unifying clinical applications in 2019.[3]
  • 77% of surveyed CROs used standalone electronic trial master file applications in 2019.[3]
  • 93% of surveyed CROs used standalone electronic data-capture applications in 2019.[3]
  • 78% of surveyed CROs relied on manual spreadsheets to manage study start-up in 2019.[3]

Data analytics in the contract research organization industry

  • 1.2 billion non-identified patient records were held by IQVIA in 2025.[10]
  • 65% of CRO survey respondents said sponsor-provided data was rarely immediately usable in 2025.[11]
  • 68 petabytes of unique data were held by IQVIA in 2025.[10]
  • 4,000 advanced analytics experts, data scientists and statisticians worked at IQVIA in 2025.[10]
  • 82% of CRO survey respondents created specifications for analysis-ready datasets in 2025.[11]
  • 90% of global pharmaceutical sales were tracked by IQVIA’s data suppliers in 2025.[10]

Data Quality in the healthcare services sector (sector benchmark)

  • 75% of U.S. healthcare organizations represented in the survey predominantly used clinical registry data for quality and process improvement in 2024.[12]
  • 40% of U.S. healthcare clinical data abstractors reported that manual data entry hampers clinical registry efforts in 2024.[12]
  • 50% of U.S. healthcare clinical data abstractors reported that data inaccuracies hamper clinical registry efforts in 2024.[12]
  • 40% of U.S. healthcare clinical data abstractors reported that incomplete data hampers clinical registry efforts in 2024.[12]
  • 8% of U.S. healthcare organizations rated their provider data as excellent in 2022.[13]

Data Governance in the healthcare services sector (sector benchmark)

  • 77% of healthcare organizations reported that their governance functions met at least quarterly in 2025.[13]
  • 10% of healthcare organizations managed data governance exclusively within IT in 2025.[13]
  • 72% of healthcare organizations operated governance using approved policy and standards frameworks in 2025.[13]
  • 38% of healthcare organizations had formal data and information quality-management statements in 2025.[13]
  • 39% of healthcare organizations reported having a formally chartered data-governance function in 2025.[13]
  • 66% of healthcare organizations reported multidisciplinary representation in governance, including patient or consumer representatives, in 2025.[13]

KPIs in the contract research organization industry

  • 9 days was the median time from receipt of a study budget to its return across more than 2,200 U.S. research sites in 2026.[14]
  • $1,311 was the median revenue per patient visit across more than 2,200 U.S. research sites in 2026.[14]
  • 32% of ongoing CRO-managed clinical trials used quality-tolerance limits in 2024.[1]
  • 6 eSource builds per study was the median across more than 2,200 U.S. research sites in 2026.[14]
  • 11 days was the median time from eSource creation to publication across more than 2,200 U.S. research sites in 2026.[14]
  • 51% of ongoing CRO-managed clinical trials used key risk indicators specific to data quality or patient safety in 2024.[1]

06 Statistics

Strategy & Growth

Market demand is extending outward while delivery capacity grows: the global CRO market is projected at $93.02 billion in 2026 and is forecast to reach $199.28 billion by 2034.

Growth in the contract research organization industry

  • $8,281.7 million was ICON’s 2024 revenue, up 2.0% year over year.[15]
  • $61.2 billion is the projected global CRO market value for 2026.[16]
  • $57.5 billion was the global CRO market value in 2025, according to Global Market Insights.[16]
  • $129.8 billion is the projected global CRO market value for 2029 in the MarketsandMarkets estimate cited by Contract Pharma.[17]
  • $9,974 million was ICON’s 2024 full-year net business wins.[15]
  • 1.20 was ICON’s 2024 net book-to-bill ratio.[15]

Differentiation in the contract research organization industry

  • 763,500-plus patients were supported by ICON from January 2023 through January 2026.[15]
  • 36.0% of ICON’s 2024 revenue came from the United States.[18]
  • 52.6% of ICON’s 2024 revenue came from Europe.[18]
  • 20,000 employees worked for Charles River Laboratories worldwide in 2024.[18]
  • 61% of Charles River’s 2024 revenue came from its largest business segment.[18]
  • 2,304 studies were supported by ICON from January 2023 through January 2026.[15]

Mergers and acquisitions in the contract research organization industry

  • 60% of Japan’s CMIC was acquired by Blackstone in 2025.[19]
  • 160-plus employees worked for Japan’s Micron when Tigermed completed its acquisition in 2025.[20]
  • 18 U.S. locations comprised CenExel’s clinical site network when BayPine acquired a majority stake in 2025.[19]
  • $92.5 million was the consideration for ICON’s acquisition of KCR in 2024.[18]
  • 40% of CMIC remained owned by CMIC’s holding company after Blackstone’s 2025 transaction.[19]
  • $1.9 billion-plus was the valuation reported for Novotech after a 2025 stake transaction.[19]

Strategic partnerships in the contract research organization industry

  • 46 service providers were evaluated in the 2024 CRO Leadership Awards customer survey used by ICON.[15]
  • $5 million was the value of IQVIA’s partnership supporting The Global Fund’s laboratory system.[21]
  • More than 300 patient organizations worked with IQVIA on research and technology relationships.[21]
  • 20-plus performance metrics were used in the 2024 CRO Leadership Awards survey cited by ICON.[15]
  • Nearly 400 global OCE customers in more than 130 countries were supported by IQVIA through its Salesforce partnership in 2024.[10]
  • One new full-service partnership with a top-30 pharmaceutical customer was announced by ICON in the second quarter of 2024.[15]

07 Statistics

People & Workforce

Workforce presence supports sustained delivery, with 470,000+ CRO employees in 2025 and ACRO members reporting more than 470,000 employees worldwide in 2025.

Hiring in the contract research organization industry

  • 3% was Labcorp’s workforce growth in 2024 through organic growth and acquisitions.[22]
  • 87,000 employees worked at IQVIA globally in 2023.[10]
  • Nearly 70,000 employees worked at Labcorp in approximately 100 countries in 2024.[22]
  • 88,000 employees worked at IQVIA worldwide in 2024.[10]
  • 41,100 employees worked at ICON in 106 locations across 53 countries at December 31, 2023.[18]

Employee retention in the contract research organization industry

  • 87% of IQVIA employees saw a clear link between their work and the company’s shared vision in 2023.[10]
  • 118 employee-resource-group chapters operated across eight countries at Labcorp in 2024.[2]
  • 75 or more clients were served by IQVIA’s dedicated global public-health business launched in 2023, supporting workforce growth in that business.[10]
  • 9 employee-resource groups operated at Labcorp in 2024.[2]
  • 5.3 years was overall employee tenure in BDO’s 2024 global CRO compensation and turnover survey.[23]

Remote Work in the healthcare services sector (sector benchmark)

  • Across U.S. health care and social assistance, 18% of full-time employees worked fully from home during December 2024–March 2025.[24]
  • Across U.S. medical groups, 18% of leaders expected their organization’s share of remote or hybrid jobs to decrease during 2024.[25]
  • Across U.S. medical groups, 52% reported that 1%–25% of their workforce worked remotely at least 50% of the time.[25]
  • Across U.S. medical groups, 22% of leaders expected their organization’s share of remote or hybrid jobs to increase during 2024.[25]

Hybrid Work in the healthcare services sector (sector benchmark)

  • Across U.S. healthcare support roles, 14% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[25]
  • Across U.S. health care and social assistance, 24% of full-time employees were in hybrid arrangements during December 2024–March 2025.[24]
  • Across U.S. healthcare practitioners and technical roles, 16% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[25]
  • About 6% of U.S. healthcare jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[25]
  • About 12% of nonclinical healthcare administrative and customer-support jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[25]

Upskilling in the contract research organization industry

  • 30 days is the maximum period for Fortrea new employees to receive modern-slavery awareness training.[26]
  • 1.1 million or more training and professional-development hours were completed by Labcorp employees during 2024.[22]
  • 5 points above the Fortune 500 benchmark was IQVIA’s 2023 employee score for seeing a clear link between work and the company vision.[10]
  • 88% of IQVIA employees said they were acquiring the skills needed to be successful in 2023.[10]
  • 7 points above the Fortune 500 benchmark was IQVIA’s 2023 employee score for acquiring skills needed for success.[10]

Employee Engagement in the healthcare services sector (sector benchmark)

  • Across U.S. healthcare organizations, employee turnover fell from 20% to 18% in 2024.[27]
  • U.S. registered nurses with low teamwork scores were 1.53 times more likely to leave their healthcare organization in 2024.[27]
  • Across NHS staff, the national staff-engagement theme score was 6.64 in the second quarter of 2024/25.[28]
  • Across 2.3 million U.S. healthcare workers, employee engagement declined by 0.02 points in 2024.[27]
  • Among U.S. healthcare advanced practice providers, 52% felt heard in 2024.[27]

DEI in the contract research organization industry

  • 16% of IQVIA’s U.S. employees identified as Asian in 2024.[10]

08 Statistics

Customer & Sales

Retention and contracted work volume matter: ACRO members reported 592 sponsor companies supported in 2025, tied to 7,634 studies involving 1.4 million patients and volunteers.

Customer experience in the contract research organization industry

  • 95% of PSI’s clinical studies delivered first-patient-in on schedule in 2025, globally.[29]
  • 97% of PSI’s clinical studies delivered last-patient-in on schedule in 2025, globally.[29]
  • 95% of PSI’s clinical studies delivered database lock on schedule in 2025, globally.[29]
  • 97% of PSI’s clinical studies delivered the clinical study report on schedule in 2025, globally.[29]

Customer retention in the contract research organization industry

  • 90% of Evotec’s 2020 revenue came from repeat customers, globally.[30]
  • 90% of Evotec’s 2025 revenue came from customers that had also purchased services in the previous year, globally.[18]
  • 93% of Evotec’s 2023 revenue came from repeat customers, globally.[30]
  • 94% of Evotec’s 2024 revenue came from repeat customers, globally.[30]
  • 92% of Evotec’s 2022 revenue came from repeat customers, globally.[30]

Customer acquisition in the contract research organization industry

  • 292 new customers were added by Evotec in 2024, globally.[30]
  • 325 new customers were added by Evotec in 2022, globally.[30]
  • 225 new customers were added by Evotec in 2025, globally.[18]
  • 52% growth in new customers was reported by PSI in 2025, globally.[29]
  • Almost 400 new clinical-research customers were added by IQVIA in 2023, globally.[18]

Customer loyalty in the contract research organization industry

  • 93% of Evotec’s business was repeat business in 2023, globally.[30]
  • 39% of Evotec’s 2022 revenue came from its ten largest customers, globally.[30]
  • 52% of Evotec’s 2024 revenue came from its ten largest customers, globally.[30]
  • 93% of PSI’s business was repeat business in 2025, globally.[29]
  • 47% of Evotec’s 2023 revenue came from its ten largest customers, globally.[30]

Lead generation in the contract research organization industry

  • $8.4 billion in services net new-business awards were reported by IQVIA in 2023, globally.[18]
  • 1.33x was IQVIA’s 2023 clinical-research book-to-bill ratio excluding reimbursed expenses, globally.[18]
  • 1.28x was IQVIA’s 2023 clinical-research book-to-bill ratio including reimbursed expenses, globally.[18]
  • $29.7 billion was IQVIA’s clinical-research contracted backlog at the end of 2023, globally.[18]
  • More than 50% of PSI’s workload came directly from referrals and repeat business in 2014, globally.[31]

09 Statistics

Marketing & Brand

Competition increasingly relies on measured digital presence, and CROs regularly analyzed competitors in 2024 (65% of respondents).

Marketing in the contract research organization industry

  • 38% of drug-development-services companies handled market research internally in 2024.[32]
  • 35% of drug-development-services companies handled advertising internally in 2024.[32]
  • 47% of CROs contracted work through an external marketing agency in 2024, down from 71% in 2023.[32]
  • 48% of drug-development-services companies handled marketing collateral internally in 2024.[32]
  • 65% of CROs regularly analyzed competitors in 2024.[32]

Digital marketing in the contract research organization industry

  • CROs rated live social-media events 2.80 out of 5 for digital-marketing effectiveness in 2024.[32]
  • Aptuit increased website traffic by 1,600% through a six-month inbound-marketing program.[33]
  • 20% of CROs used artificial intelligence for public relations or media in 2024.[32]
  • CROs rated webinars 3.31 out of 5 for digital-marketing effectiveness in 2024.[32]
  • 74% of drug-development-services companies used social-media advertising in 2022.[32]

Branding in the contract research organization industry

  • Parexel ranked among the top two global CROs for service-provider leadership in 2021.[34]
  • 237 biopharmaceutical professionals evaluated 39 CROs on brand-related and performance metrics in the 2021 ISR survey.[34]
  • Parexel ranked among the top two global CROs for familiarity in the 2021 Phase II/III benchmark.[34]
  • Parexel achieved the highest brand-performance score among 39 CROs evaluated in a 2021 Phase II/III survey.[34]
  • Parexel ranked first among global CROs for customer loyalty in the 2021 Phase II/III benchmark.[34]

Social media in the contract research organization industry

  • X received an average effectiveness rating of 2.37 out of 5 among drug-development-services companies in 2024.[32]
  • 6% of CROs increased social-media marketing spend from 2023 to 2024.[32]
  • 26% of drug-development-services companies outsourced some or all social-media work in 2024.[32]
  • 28% of drug-development-services companies outsourced some or all social-media work in 2021.[32]
  • YouTube received an average effectiveness rating of 3.23 out of 5 among drug-development-services companies in 2024.[32]

Influencer Marketing in the healthcare services sector (sector benchmark)

  • 92% of U.S.-focused health and wellness influencers included product or service promotions at least occasionally in 2026.[35]
  • 33% of U.S.-focused health and wellness influencers promoted a product, service or subscription in more than half of their posts in 2026.[35]
  • 50% of U.S. physicians surveyed had changed prescribing choices based on healthcare influencer or KOL content on social media in 2024.[36]
  • 38% of posts from U.S.-focused health and wellness influencers promoted a product, service or subscription in 2026.[35]
  • 8.57 million influencer posts about the health industry generated a 1.07% average engagement rate globally in 2023.[37]

10 Statistics

Operations & Execution

Operational execution leans on trial-master-file and eSource timing measures, including a 9-day median from study budget receipt to return across more than 2,200 U.S. research sites in 2026.

Process optimization in the contract research organization industry

  • 70% of CRO respondents used a purpose-built electronic trial master file application in 2020, compared with 21% in 2014.[38]
  • 74% of CRO respondents identified reducing manual processes as a top driver for unified clinical operations in 2020.[38]
  • 57% of CRO respondents said improving collaboration between sponsors, CROs and sites was a primary reason to streamline information exchange in 2020.[38]
  • 50% of CRO respondents cited easier collaboration with study partners as a top driver for unified clinical operations in 2020.[38]
  • 60% of CRO respondents cited faster study execution as a top driver for unified clinical operations in 2020.[38]

Operational efficiency in the contract research organization industry

  • 63% of CROs using purpose-built CTMS applications reported more effective monitoring in 2020.[38]
  • Operational efficiency increased 42% between 2012 and 2021 in the CRO sample studied.[39]
  • 29% of CRO respondents in a 2025 clinical data survey attributed workflow inefficiency mainly to process issues.[38]
  • 49% of CRO respondents in a 2025 clinical data survey said technology and process issues contributed equally to workflow inefficiency.[38]
  • 67% of CROs using purpose-built CTMS applications reported better compliance with standards in 2020.[38]

Quality management in the contract research organization industry

  • 84% of pharmaceutical-company respondents used standardized tools for CRO oversight in a German survey.[40]
  • 95% of pharmaceutical-company respondents used a RACI responsibility matrix to support CRO oversight in the German survey.[40]
  • 76% of pharmaceutical-company respondents had a CRO-oversight training program available in the German survey.[40]
  • 75% of pharmaceutical-company respondents conducted risk-based CRO oversight based on previous experience in the German survey.[40]
  • 55% of CRO respondents reported that eTMF modernization improved trial-master-file timeliness in 2020.[38]

Supply chain in the contract research organization industry

  • 46% of CRO respondents identified site essential-document collection as a major study-start-up challenge in 2020.[38]
  • 81% of CRO respondents used email to exchange trial data and documents with sites in 2020.[38]
  • 41% of 2026 clinical-supply survey respondents identified reducing supply delays as the single most critical priority for 2026.[41]
  • 52% of CRO respondents identified site identification, feasibility and selection as a major study-start-up challenge in 2020.[38]
  • 35% of CRO respondents used eTMF systems to exchange trial data and documents with sites in 2020.[38]

Outsourcing / Offshoring in the healthcare services sector (sector benchmark)

  • 20% of U.S. medical-group leaders planned to outsource or automate some revenue-cycle-management activities in 2024, according to an MGMA poll with 262 responses.[25]
  • 29% of global healthcare providers used third-party providers for remote patient monitoring in 2024, based on a survey of 28 healthcare-provider executives.[42]
  • 46% of global healthcare providers used third-party providers for customer-experience services in 2024, based on a survey of 28 healthcare-provider executives.[42]
  • 54% of global healthcare providers used third-party providers for supply-chain services in 2024, based on a survey of 28 healthcare-provider executives.[42]
  • 43% of global healthcare providers used third-party providers for payroll services in 2024, based on a survey of 28 healthcare-provider executives.[42]

11 Statistics

Finance & Pricing

Pricing and delivery economics track contract momentum: Fortrea reported $7.728 billion backlog at December 31, 2025, and Medpace backlog was $3.0272 billion at December 31, 2025.

Pricing strategy in the contract research organization industry

  • 24.8% of ICON’s 2025 revenue came from its five largest customers, creating concentration considerations for pricing and negotiation strategy.[18]
  • 64.0% of ICON’s 2025 revenue came from its 25 largest customers, highlighting the importance of account-level pricing management.[18]
  • $3.0272 billion was Medpace’s backlog at December 31, 2025, up 4.3% from $2.9022 billion a year earlier.[18]
  • 1.09x was ICON’s 2025 book-to-bill ratio after $11.867 billion of gross business wins and $2.834 billion of cancellations.[18]
  • $7.728 billion was Fortrea’s backlog at December 31, 2025, providing the contracted base against which pricing and delivery economics are managed.[18]

Cost reduction in the contract research organization industry

  • 2.0% was the 2025 increase in IQVIA Research & Development Solutions’ selling, general and administrative expenses.[18]
  • $79.069 million was ICON’s 2025 restructuring expense, compared with $92.123 million in 2024.[18]
  • $7 million was IQVIA’s 2025 increase in total selling, general and administrative expenses, despite the $51 million corporate-expense reduction.[18]
  • 7.5% was the 2025 increase in IQVIA Research & Development Solutions’ cost of revenues, excluding depreciation and amortization.[18]
  • Approximately 20 smaller Charles River sites were planned for consolidation as part of its cost-reduction program.[18]

Profitability in the contract research organization industry

  • 19.1% was Medpace’s fourth-quarter 2025 net-income margin, compared with 21.8% in the fourth quarter of 2024.[18]
  • $40.4 million was Fortrea’s adjusted net income for 2025, compared with $30.1 million in 2024.[18]
  • 5.2% was ICON’s 2025 operating-profit margin including exceptional items, compared with 12.7% in 2024.[43]
  • $144.3 million was Charles River’s 2025 net loss available to common shareholders, compared with $10.3 million of net income in 2024.[18]
  • $25.2 million was Charles River’s 2025 operating income, compared with $227.3 million in 2024.[18]

Financial planning in the contract research organization industry

  • $1.980 billion was IQVIA’s cash and cash equivalents at December 31, 2025.[21]
  • $7.850 billion to $8.150 billion was ICON’s 2026 revenue guidance range.[43]
  • $190 million to $220 million was Fortrea’s 2026 adjusted EBITDA guidance range.[18]
  • $2.550 billion to $2.650 billion was Fortrea’s 2026 revenue guidance range.[18]
  • $2.1 billion was IQVIA’s 2025 free cash flow.[18]

12 Statistics

Product & Service

AI usage in study operations is reported at the CRO level, with 64% using data-driven AI for protocol optimization during project start-up in 2025.

Product development in the contract research organization industry

  • 64% of ACRO member CROs used data-driven AI for protocol optimization during project start-up in 2025.[1]
  • 71% of ACRO member CROs used AI for strategic study-feasibility optimization in 2025.[1]
  • 71% of ACRO member CROs used AI for site selection and activation during project start-up in 2025.[1]
  • 7,634 studies were conducted or participated in by ACRO member CROs in 2025 across global therapeutic areas and geographies.[1]
  • 148 global multi-regional clinical-trial projects represented Tigermed’s cumulative experience at December 31, 2024.[20]

Product lifecycle in the contract research organization industry

  • 64% of ACRO member CROs used AI for data management during study conduct in 2025.[1]
  • Nearly 950 active vaccine trials were conducted by ACRO member CROs in 2025 across all study phases.[1]
  • Nearly 20% of ACRO member CROs reported that FDA review and inspection timeliness worsened during 2025.[1]
  • 562 active vaccine trials were conducted by ACRO member CROs in 2024.[1]
  • 86% of ACRO member CROs contributed to COVID-19 or seasonal-influenza vaccine markets in 2025.[1]

After-sales in the contract research organization industry

  • 27% of ACRO member CRO customers were biotechnology companies in 2025.[1]
  • 3% of ACRO member CRO customers were medical-device companies in 2025.[1]
  • More than 250 scientific papers were published by IQVIA in 2024, including more than 15 on responsible AI use.[18]
  • 17 IQVIA laboratories were My Green Lab certified in 2024.[18]
  • 57% of ACRO member CRO customers were pharmaceutical companies in 2025.[1]

Value proposition in the contract research organization industry

  • $0.7 billion was IQVIA’s 2024 revenue from Contract Sales and Medical Solutions.[18]
  • Approximately 400 net new clinical-research customers were added by IQVIA’s R&DS business in 2024.[18]
  • $7.9 billion of IQVIA’s clinical-development backlog was expected to convert to revenue during the twelve months after December 31, 2024.[10]
  • $10.1 billion was IQVIA’s contracted R&DS net new business at the end of 2024.[18]
  • 100% of applicable IQVIA clinical-technology products used AI and automation in 2024.[18]

13 Statistics

Sustainability & Ethics

Sustainability reporting connects to operational changes, including a 38% decrease in Labcorp’s Scope 1 and 2 market-based emissions per million dollars of revenue versus 2020.

Sustainability in the contract research organization industry

  • 17% reduction in total emissions was reported by TFS HealthScience in 2025 worldwide.[44]
  • 384 metric tons of CO2e in laboratory freezer waste were avoided by IQVIA in 2024 worldwide.[10]
  • 48% of Parexel’s global office occupancy was in green buildings in 2024.[45]
  • 44% reduction in air-travel emissions from Parexel’s 2019 baseline was reported for 2024 worldwide.[45]
  • 50% of IQVIA suppliers had set or committed to set emissions-reduction goals in 2024 worldwide.[10]

ESG in the contract research organization industry

  • 38% decrease in Labcorp’s Scope 1 and 2 market-based emissions per million dollars of revenue was reported versus 2020.[22]
  • Five additional IQVIA laboratories achieved My Green Lab certification during 2024.[10]
  • $89.4 billion in revenue was generated by 15 ACRO member CRO and technology companies in 2025.[1]
  • More than 10,000 life-sciences and healthcare customers in over 100 countries were served by IQVIA in 2024.[10]
  • 25% reduction in Parexel’s targeted absolute Scope 3 emissions is planned by 2030 from its 2022 baseline.[45]

Ethics in the contract research organization industry

  • 1% of matters received by IQVIA’s Ethics and Compliance Office in 2023–2024 concerned third-party matters.[10]
  • 100% of Parexel employees were covered by the company’s global compliance and ethics framework in 2024.[45]
  • 94.5% of IQVIA employees said they knew how to report ethical concerns or observed misconduct in 2024 worldwide.[10]
  • 27% of matters received by IQVIA’s Ethics and Compliance Office in 2023–2024 concerned business matters.[10]
  • 38% of matters received by IQVIA’s Ethics and Compliance Office in 2023–2024 were inquiries seeking guidance on ethical conduct.[10]

CSR in the contract research organization industry

  • 592 sponsor companies were supported by ACRO member CRO companies in 2025.[1]
  • 5,000+ Parexel employees participated in 15 global Patients First Fridays sessions in 2024.[45]
  • More than 100 countries were covered by IQVIA’s clinical research, healthcare intelligence and commercial activities in 2024.[10]
  • 1.4 million patients and volunteers were managed or supported in studies involving ACRO member CROs in 2025.[1]

Circular economy in the contract research organization industry

  • Almost 3 metric tons of single-use plastic were removed from IQVIA clinical-trial test kits in 2024.[10]
  • Parexel reported waste procedures covering treatment, disposal, reuse, recycling and increased circularity efforts in its global operations in 2024.[45]
  • 384 metric tons of CO2e were avoided through IQVIA laboratory freezer-waste initiatives in 2024.[10]

Carbon footprint in the contract research organization industry

  • 2% of IQVIA’s 2024 Scope 3 emissions came from employee commuting worldwide.[10]
  • 42% reduction in Parexel’s absolute Scope 1 emissions is targeted by 2030 from its 2022 baseline worldwide.[45]
  • 16% of IQVIA’s 2024 Scope 3 emissions came from upstream transport and distribution worldwide.[10]
  • 1% of IQVIA’s 2024 Scope 3 emissions came from fuel- and energy-related activities outside Scope 1 and Scope 2 worldwide.[10]
  • 20% of IQVIA’s 2024 Scope 3 emissions came from business travel worldwide.[10]

15 Statistics

Globalization & Expansion

Global delivery footprint stays a core variable, with North America at a 50.08% share in 2025 and Asia Pacific projected to reach $19.45 billion in 2026.

Globalization in the contract research organization industry

  • PSI CRO employed more than 3,200 people across 58 countries at December 31, 2025.[29]
  • Labcorp employed nearly 71,000 people across 17 countries at December 31, 2025.[18]
  • 93,000 IQVIA employees worked in more than 100 countries in 2025, supporting global clinical research, healthcare intelligence and commercialization services.[18]
  • 11.5% of ICON’s 2025 revenue was generated in the rest of the world outside the United States and Europe.[18]
  • $5,185 million of IQVIA revenue came from Europe and Africa in 2025 across Technology & Analytics, Research & Development, and Contract Sales & Medical Solutions.[18]

Cultural adaptation in the contract research organization industry

  • 53% of IQVIA employees worldwide at manager level identified as female in 2024.[18]
  • 79% of IQVIA employees said they felt they belonged at the company in the 2023 employee pulse survey.[18]
  • 87% of IQVIA employees said they saw a clear link between their work and the company’s shared vision in the 2023 employee pulse survey.[18]
  • 62% of IQVIA employees globally identified as female in 2024.[18]
  • IQVIA’s eight global employee resource groups had almost 12,000 members across 73 countries in 2023.[18]

Stakeholder management in the contract research organization industry

  • No individual ICON customer contributed more than 10% of revenue in 2025.[18]
  • 64.0% of ICON’s 2025 revenue came from its 25 largest customers.[18]
  • $576.265 million was ICON’s revenue from its top client in 2025.[18]
  • IQVIA served nearly all of the top 100 global pharmaceutical and biotechnology companies in 2025.[18]
  • PSI CRO reported a 93% repeat-business rate in 2025, indicating continued customer retention.[29]

Distribution channels in the contract research organization industry

  • PSI CRO reported 52% new-customer growth in 2025.[29]
  • ICON reported $8,251.340 million in total revenue for 2025 from outsourced development services.[18]
  • IQVIA’s Contract Sales & Medical Solutions revenue totaled $266 million in Europe and Africa in 2025.[18]
  • IQVIA’s Research & Development Solutions revenue totaled $8,896 million globally in 2025, representing its largest reported service channel.[18]
  • PSI CRO reported 15% revenue growth in 2025 through its global delivery model.[29]

Key questions about the contract research organization industry

What is the global CRO services market size in 2025 and the 2026 estimate?
The global contract research organization services market was valued at $92.27 billion in 2025 and is projected to reach $99.87 billion in 2026.
What growth rate should analysts use for 2026–2034?
The forecast CAGR for 2026–2034 is 9.0%, with the market forecast to reach $199.28 billion by 2034.
Which companies lead the contract research organization industry?
IQVIA stands out for Research & Development Solutions delivery because it reported $8.896 billion in 2025 revenue, while Labcorp is the pick for drug development laboratory work since it provides capabilities serving clients in about 100 countries.
How are technology and workflow practices changing across the sector?
ACRO member activity included 7,634 studies in 2025 across clinical research operations that can use automated workflows, and 64% of ACRO member CROs used AI for data management during study conduct in 2025.
How is the market structured by service focus?
Early-phase development services represented the largest service segment with a 40.74% share in 2025, and oncology is projected to hold a 29.7% share in 2026.
What compliance or conduct issues create material operational risk?
The FDA said in 2025 that certain studies conducted by Raptim Research were unacceptable due to data-integrity and study-conduct concerns.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Contract Research Organization Industry Statistics. Gitnux. https://gitnux.org/contract-research-organization-industry-statistics
MLA
Samuel Norberg. "Contract Research Organization Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/contract-research-organization-industry-statistics.
Chicago
Samuel Norberg. 2026. "Contract Research Organization Industry Statistics." Gitnux. https://gitnux.org/contract-research-organization-industry-statistics.

Sources & references

60 sources cited across this report

  1. acrohealth.org
  2. ir.labcorp.com
  3. acrpnet.org
  4. deloitte.com
  5. healthit.gov
  6. business.adobe.com
  7. kpmg.com
  8. go.rackspace.com
  9. cetic.br
  10. iqvia.com
  11. link.springer.com
  12. carta.healthcare
  13. intersystems.com
  14. clinicalresearch.io
  15. iconplc.com
  16. gminsights.com
  17. ppd.com
  18. sec.gov
  19. fiercebiotech.com
  20. tigermedgrp.com
  21. ir.iqvia.com
  22. labcorp.com
  23. bdo.com
  24. wfhresearch.com
  25. mgma.com
  26. fortrea.com
  27. pressganey.com
  28. england.nhs.uk
  29. psi-cro.com
  30. evotec.com
  31. alpha.pharma.kalyna.dev
  32. scorrmarketing.com
  33. biostratamarketing.com
  34. newsroom.parexel.com
  35. pewresearch.org
  36. sermo.com
  37. media.sproutsocial.com
  38. veeva.com
  39. onlinelibrary.wiley.com
  40. doi.org
  41. myonex.com
  42. tcs.com
  43. investor.iconplc.com
  44. tfscro.com
  45. parexel.com
  46. fda.gov
  47. ache.org
  48. proofpoint.com
  49. ponemonsullivanreport.com
  50. kff.org
  51. hfmmagazine.com
  52. sophos.com
  53. fortunebusinessinsights.com
  54. marketsandmarkets.com
  55. financialfilings.com
  56. investor.medpace.com
  57. ir.criver.com
  58. syneoshealth.com
  59. altasciences.com
  60. worldwide.com